Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon-β therapy

European Journal of Neurology

Volumn 21, Issue 3, 2014, Pages

  Freedman, M S ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Disease modifying drugs; Fingolimod; Natalizumab; Relapsing remitting multiple sclerosis; Treatment failure; Treatment strategy

Indexed keywords

DISEASE-MODIFYING DRUGS; FINGOLIMOD; NATALIZUMAB; RELAPSING-REMITTING MULTIPLE SCLEROSIS; TREATMENT FAILURE; TREATMENT STRATEGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; DATABASES, BIBLIOGRAPHIC; DECISION MAKING; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MULTIPLE SCLEROSIS; PROPYLENE GLYCOLS; SPHINGOSINE;

EID: 84893856323     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12299     Document Type: Review

References (88)

1. Rio J, Comabella M, Montalban X. Multiple sclerosis: current treatment algorithms. Curr Opin Neurol 2011; 24: 230-237.
2. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000; 343: 898-904.
3. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576-1582.
4. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67: 1242-1249.
5. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009; 374: 1503-1511.
6. Comi G, De Stefano N, Freedman MS, et al. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol 2012; 11: 33-41.
7. Maurer M, Dachsel R, Domke S, et al. Health care situation of patients with relapsing-remitting multiple sclerosis receiving immunomodulatory therapy: a retrospective survey of more than 9000 German patients with MS. Eur J Neurol 2011; 18: 1036-1045.
8. La Mantia L, Munari LM, Lovati R. Glatiramer acetate for multiple sclerosis. Cochrane Database Syst Rev 2010; 5: CD004678.
9. Rice GP, Incorvaia B, Munari L, et al. Interferon in relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev 2001; 4: CD002002.
10. Portaccio E, Zipoli V, Siracusa G, et al. Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis. Eur Neurol 2008; 59: 131-135.
11. Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology 2003; 61: 551-554.
12. Zwibel HL. Glatiramer acetate in treatment-naive and prior interferon-beta-1b-treated multiple sclerosis patients. Acta Neurol Scand 2006; 113: 378-386.
13. Río J, Tintore M, Sastre-Garriga J, et al. Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response. Eur J Neurol 2012; 19: 899-904.
14. Pelletier D, Hafler DA. Fingolimod for multiple sclerosis. N Engl J Med 2012; 366: 339-347.
15. Conway D, Cohen JA. Combination therapy in multiple sclerosis. Lancet Neurol 2010; 9: 299-308.
16. Freedman MS, Cohen B, Dhib-Jalbut S, et al. Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command. Curr Med Res Opin 2009; 25: 2459-2470.
17. European Medicines Agency. Gilenya EU summary of product characteristics, 2011. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002202/WC500104528.pdf (accessed 10/02/2012).
18. European Medicines Agency. Tysabri EU summary of product characteristics, 2012. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000603/WC500044686.pdf (accessed 27/01/2012).
19. Health Canada. Tysabri Canadian product monograph, 2010. Available at: http://webprod3.hc-sc.gc.ca/dpd-bdpp/info.do?lang=eng&code=77184 (accessed 03/04/2012).
20. Health Canada. Gilenya Canadian product monograph, 2011. Available at: http://webprod3.hc-sc.gc.ca/dpd-bdpp/dispatch-repartition.do?lang=eng (accessed 13/04/2012).
21. Frohman EM, Racke MK, Raine CS. Multiple sclerosis - the plaque and its pathogenesis. N Engl J Med 2006; 354: 942-955.
22. Peterson LK, Fujinami RS. Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis. J Neuroimmunol 2007; 184: 37-44.
23. Compston A, Coles A. Multiple sclerosis. Lancet 2002; 359: 1221-1231.
24. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-285.
25. Freedman MS. Multiple sclerosis therapeutic strategies: use second-line agents as first-line agents when time is of the essence. Neurol Clin Pract 2011; 1: 66-68.
26. Freedman MS, Patry DG, Grand'Maison F, et al. Treatment optimization in multiple sclerosis. Can J Neurol Sci 2004; 31: 157-168.
27. International Working Group for Treatment Optimization in MS. Treatment optimization in multiple sclerosis: report of an international consensus meeting. Eur J Neurol 2004; 11: 43-47.
28. Karussis D, Biermann LD, Bohlega S, et al. A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting. Eur J Neurol 2006; 13: 61-71.
29. Freedman MS, Forrestal FG. Canadian treatment optimization recommendations (TOR) as a predictor of disease breakthrough in patients with multiple sclerosis treated with interferon beta-1a: analysis of the PRISMS study. Mult Scler 2008; 14: 1234-1241.
30. Rio J, Comabella M, Montalban X. Predicting responders to therapies for multiple sclerosis. Nat Rev Neurol 2009; 5: 553-560.
31. Río J, Castilló J, Rovira A, et al. Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler 2009; 15: 848-853.
32. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402-415.
33. Khatri B, Barkhof F, Comi G, et al. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol 2011; 10: 520-529.
34. Cohen JA, Barkhof F, Comi G, et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. J Neurol 2013; 260: 2023-2032.
35. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387-401.
36. Devonshire V, Havrdova E, Radue EW, et al. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol 2012; 11: 420-428.
37. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
38. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911-923.
39. ClinicalTrials.gov. Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis (SURPASS), 2012. Available at: http://clinicaltrials.gov/ct2/show/NCT01058005 (accessed 10/04/2012).
40. Belachew S, Phan-Ba R, Bartholome E, et al. Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis. Eur J Neurol 2011; 18: 240-245.
41. Castillo-Trivino T, Mowry EM, Gajofatto A, et al. Switching multiple sclerosis patients with breakthrough disease to second-line therapy. PLoS ONE 2011; 6: e16664.
42. Prosperini L, Gianni C, Leonardi L, et al. Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis. Mult Scler 2012; 18: 64-71.
43. Putzki N, Kollia K, Woods S, et al. Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis. Eur J Neurol 2009; 16: 424-426.
44. Putzki N, Yaldizli O, Buhler R, et al. Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland. Eur Neurol 2010; 63: 101-106.
45. Putzki N, Yaldizli O, Maurer M, et al. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries. Eur J Neurol 2010; 17: 31-37.
46. Deisenhammer F. Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes. CNS Drugs 2009; 23: 379-396.
47. Calabresi PA, Giovannoni G, Confavreux C, et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 2007; 69: 1391-1403.
48. Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 2010; 33: 91-101.
49. Kessler M, Goldsmith D, Schellekens H. Immunogenicity of biopharmaceuticals. Nephrol Dial Transplant 2006; 21(Suppl. 5): v9-v12.
50. Brinkmann V. FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system. Br J Pharmacol 2009; 158: 1173-1182.
51. Mehling M, Brinkmann V, Antel J, et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 2008; 71: 1261-1267.
52. Francis G, Kappos L, O'Connor P, et al. Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy. Mult Scler J 2013; doi:10.1177/1352458513500551 [Epub ahead of print].
53. Gross CM, Baumgartner A, Rauer S, et al. Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod. Neurology 2012; 79: 2006-2007.
54. Uccelli A, Ginocchio F, Mancardi GL, et al. Primary varicella zoster infection associated with fingolimod treatment. Neurology 2011; 76: 1023-1024.
55. Ratchford JN, Costello K, Reich DS, et al. Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod. Neurology 2012; 79: 2002-2004.
56. European Medicines Agency. Revised Summary of Product Characteristics. Gilenya (fingolimod), 2012. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2012/04/WC500125687.pdf (accessed 22/04/2012).
57. Novartis AG. Novartis statement: Gilenya (fingolimod) safety information update, 2012. Available at: http://www.novartis.com/downloads/newsroom/product-related-info-center/statement-PML.pdf (accessed 18/04/2012).
58. US Food and Drug Administration. Gilenya (fingolimod): Revised US prescribing information, 2012. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022527s008lbl.pdf (accessed 17/05/2012).
59. US Food and Drug Administration. Gilenya (fingolimod): Drug Safety Communication - Safety Review of a Reported Death After the First Dose. Posted 20 December 2011, 2011. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm284355.htm (accessed 19/04/2012).
60. Comi G, Kappos L, Palace J, et al. Cardiac safety of fingolimod 0.5 mg during the first dose observation in 4-month, open-label, multi-center FIRST study in patients with relapsing MS. Neurology 2012; 17: S41.
61. Novartis AG. Frequently Asked Questions: Reported multiple sclerosis (MS) deaths of patients on Gilenya from any cause through December 13, 2011. Available at: http://www.novartis.com/downloads/newsroom/product-related-info-center/gylenia-faq.pdf; (accessed 13/03/2012).
62. US Food and Drug Administration. Gilenya (fingolimod): Drug Safety Communication - Revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Gilenya (fingolimod), 2012. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm303192.htm (accessed 17/05/2012).
63. Novartis AG. Novartis statement on reported multiple sclerosis (MS) deaths of patients on Gilenya (fingolimod) from any cause through December 13, 2011. Available at: http://www.novartis.com/downloads/newsroom/product-related-info-center/statement.pdf (accessed 13/03/2012).
64. Zarbin M, Reder AT, Collins W, et al. Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis (MS). Neurology 2011; 76(Suppl. 4): A238.
65. Lee AG. Oral MS drug may increase risk for macular edema: a report from the North American Neuro-Ophthalmology Society (NANOS) and the AAO ONE Neuro-Ophthalmology Committee, 2011. Available at: http://www.nanosweb.org/files/public/MS_drug_may_increase_risk_for_RVO1NOTRACK2lf.pdf (accessed 04/04/2012).
66. Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 2010; 9: 425-437.
67. Biogen-Idec. Natalizumab-associated PML update: March 2013, 2013. Available at: http://www.biogenidec-international.com/tysabri.aspx?ID=4763 (accessed 01/04/2013).
68. Vermersch P, Kappos L, Gold R, et al. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology 2011; 76: 1697-1704.
69. Metz I, Radue EW, Oterino A, et al. Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy. Acta Neuropathol 2012; 123: 235-245.
70. U.S. Food and Drug Administration. Tysabri US prescribing information. Revised January 2012. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125104s0576lbl.pdf (accessed 03/04/2012).
71. US Food and Drug Administration. FDA Drug Safety Communication: New risk factor for Progressive Multifocal Leukoencephalopathy (PML) associated with Tysabri (natalizumab), 2012. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm288186.htm (accessed 20/04/2012).
72. Bozic C, Richman S, Plavina T, et al. Anti-John Cunningham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol 2011; 70: 742-750.
73. Sorensen PS, Bertolotto A, Edan G, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 2012; 18: 143-152.
74. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 2010; 68: 295-303.
75. Bettin M, Lin J, Sadiq S. Accurate risk assessment for the development of PML in natalizumab treated MS patients requires CSF analysis. Neurology 2012; 77: P07.056.
76. Phan-Ba R, Lommers E, Tshibanda L, et al. MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy. J Neurol Neurosurg Psychiatry 2012; 83: 224-226.
77. Phan-Ba R, Bisig B, Deprez M, et al. Primary central nervous system lymphoma in a patient treated with natalizumab. Ann Neurol 2011; 69: 1060-1061. Author reply 1061-1062.
78. Schweikert A, Kremer M, Ringel F, et al. Primary central nervous system lymphoma in a patient treated with natalizumab. Ann Neurol 2009; 66: 403-406.
79. Bezabeh S, Flowers CM, Kortepeter C, et al. Clinically significant liver injury in patients treated with natalizumab. Aliment Pharmacol Ther 2010; 31: 1028-1035.
80. Berger JR, Centonze D, Comi G, et al. Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. Ann Neurol 2010; 68: 409-411.
81. Miravalle A, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol 2011; 68: 186-191.
82. Killestein J, Vennegoor A, Strijbis EM, et al. Natalizumab drug holiday in multiple sclerosis: poorly tolerated. Ann Neurol 2010; 68: 392-395.
83. West TW, Cree BA. Natalizumab dosage suspension: are we helping or hurting? Ann Neurol 2010; 68: 395-399.
84. West TW, Killestein J, Fox RJ. Natalizumab discontinuation: an increasingly tricky proposition. Eur J Neurol 2012; 19: 663-664.
85. Hakiki B, Portaccio E, Giannini M, et al. Withdrawal of fingolimod treatment for relapsing-remitting multiple sclerosis: report of six cases. Mult Scler 2012; 18: 1636-1639.
86. Havla JB, Pellkofer HL, Meinl I, et al. Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment. Arch Neurol 2012; 69: 262-264.
87. Ghezzi A, Rocca MA, Baroncini D, et al. Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients. J Neurol 2013; 260: 327-329.
88. De Vera A, Kappos L, Zhang-Auberson L, et al., editors. Pooled efficacy data demonstrate that fingolimod reduces multiple sclerosis relapse rate with no evidence of rebound after discontinuing treatment. Poster 844 presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis and the 15th Annual Conference of Rehabilitation in MS; 13-16 October 2010; Gothenburg, Sweden.